GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of three years of biopsy threads, summarised so you do not have to read them — 68 comments in the full submission. View in context.
1.2k
c/survodutide·submitted 1 year ago by u/quant_not_qual

three years of biopsy threads, summarised so you do not have to read them

Discussionbranch of 8 comments

Been lurking in c/t2dglp1 for about 7 months and finally have something worth posting. Short version: week 68, 0.25mg, and hepatic fat is the bit I still cannot get a straight answer on. I have read the wiki, I have read the last 33 threads, and the answers split roughly down the middle. What I actually want to know…

Read the full submission and all 68 comments →

This branch

8 comments, started 1 year ago
u/liver_enzyme_lizMOD122 points·1 year ago

Tracking number removed. It identifies both ends of a shipment.

replysharereportpermalink
u/cesar_ivaturi50 points·1 year ago

glucagon injection is a different vector than GLP-1

replysharereportpermalink
u/quant_not_qualOP0 points·1 year ago

the GLP-1/glucagon dual is hepatic fat, different from GIP/GLP-1

replysharereportpermalink
u/kian_ferreira1 point·1 year ago·edited

do not generalise from tirzepatide

replysharereportpermalink
u/milan_mensah0 points·1 year ago

Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.

replysharereportpermalink
u/quant_not_qualOP62 points·1 year ago

Week 73 for me and the honest summary is: 44kg down, early fullness manageable, and I have thought about food maybe four times today.

replysharereportpermalink
u/quant_not_qualOP38 points·1 year ago

Maintenance for 17 months now. Weight moves within about 3kg and the dose is a quarter of what it peaked at.

replysharereportpermalink
u/julia_mensa67 points·1 year ago

MASH claims need the trial and the biopsy endpoint

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →